Synthesis, Characterization and Evaluation of Anticancer Activity of New Pyrazole-5-carboxamide Derivatives

Abstract

In recent years, pyrazole derivatives have emerged as a potentially game-changing new family of cancer chemotherapeutic drugs. Thus, present work used six distinct cancer cell lines to test the new pyrazole-5-carboxamide derivatives for the anticancer activity. Present study includes synthesis, characterization and the ligand-based molecular docking of the compounds. The process begins with ethyl 2,4-dioxopentanoate and methylhydrazine, which was cyclized to form ethyl 1,3-dimethyl-1H-pyrazole- 5-carboxylate (2), which is then transformed to 1,3-dimethyl-1H-pyrazole-5-carbonyl chloride (3) through PCl3/I2. All the pyrazole-4-carboxamides (4a-n) were obtained by the acidic condensation of intermediate 3 with various substituted aryl amines (a-n). The antitumor activity against six cancer cell lines and one regular human cell line was measured using the MTT test. Two target proteins, human c-Met kinase and JAK1, were used in docking studies of the proposed compounds. When compared against the standard drug doxorubicin, most of the synthesized compounds (4a-n) showed the promising cytotoxicity profiles.